Status:
RECRUITING
Evaluation of the Impact of the Clinical Pharmacist in Oral Therapies in Oncology.
Lead Sponsor:
Polyclinique Lyon Nord
Conditions:
Neoplasm
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The hospital pharmacist plays a vital role at the time of the patient's first prescription in a healthcare facility, to inform the patient about his or her new therapy and create a link between the ho...
Eligibility Criteria
Inclusion
- Patient suffering from an oncological pathology (excluding hematological malignancies)
- Initiation of a specific treatment in the context of an oncological pathology: oral therapy treatment taken at home in oncology (which may follow surgery, radiotherapy or other in-patient treatments).
- Patient who has not yet started treatment or who has started treatment less than 30 days
- Patient with continuation of oral therapy dispensed in pharmacies
Exclusion
- Patients suffering from hematological malignancies
- Patient living in an institution or hospital
- Patient under treatment for more than 30 days
- Patient undergoing treatment other than oral therapy (venous or subcutaneous anticancer treatment)
- Patient whose treatment after initiation is not dispensed in a pharmacy
Key Trial Info
Start Date :
December 31 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2026
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT06980012
Start Date
December 31 2024
End Date
September 30 2026
Last Update
August 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Polyclinique Lyon Nord
Rillieux-la-Pape, France